Antisoma cancer news
Antisoma said it will seek partners for its development programs after concluding an offer period soliciting a sale of the biotech. Antisoma said it concluded the offer period to take a longer-term approach to explore strategic options for the company's assets. Antisoma also said it will not commit further investment to its development programs and will not consider any offers to issue share capital of the company.
In January, Antisoma announced plans to restructure after discontinuing development of amonafide (AS1413), which missed the primary endpoint in the Phase III ACCEDE trial for secondary acute myelogenous leukemia (AML). Antisoma also discontinued a Phase IIb trial of AS1411 to treat relapsed or refractory AML in January after data from about 45 patients showed the compound was unlikely to produce a clear benefit. Last month, Antisoma reduced headcount to about 10 as part of the restructuring. Amonafide is an ATP-independent topoisomerase II (TOP2) inhibitor and AS1411 is an anti- nucleolin aptamer (see BioCentury, March 14). ...